163 related articles for article (PubMed ID: 21466723)
1. [Anakinra in refractory adult onset Still's disease].
Vercoutere W; Starmans-Kool M; Peeters RM
Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
[TBL] [Abstract][Full Text] [Related]
2. Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts.
Leavis HL; van Daele PLA; Mulders-Manders C; Michels R; Rutgers A; Legger E; Bijl M; Hak EA; Lam-Tse WK; Bonte-Mineur F; Fretter P; Simon A; van Paassen P; van der Goes MC; Flendrie M; Vercoutere W; van Lieshout AWT; Leek A; Vastert SJ; Tas SW
Rheumatology (Oxford); 2024 May; 63(6):1656-1663. PubMed ID: 37669122
[TBL] [Abstract][Full Text] [Related]
3. Case Report: A Rare Case of Elderly-Onset Adult-Onset Still's Disease in a Patient With Systemic Lupus Erythematosus.
Hirooka Y; Okuda S; Sugiyama M; Shiga T; Nozaki Y; Kinoshita K; Funauchi M; Matsumura I
Front Immunol; 2022; 13():822169. PubMed ID: 35116046
[TBL] [Abstract][Full Text] [Related]
4. Refractory Adult-onset Still's Disease Treated with a Combination of Methotrexate and Etanercept.
El Hasbani G; Ahmad Y; Cassetta M
Curr Rheumatol Rev; 2024; 20(2):219-222. PubMed ID: 37855287
[TBL] [Abstract][Full Text] [Related]
5. Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options.
Bindoli S; Baggio C; Doria A; Sfriso P
Drugs; 2024 Mar; 84(3):257-274. PubMed ID: 38441807
[TBL] [Abstract][Full Text] [Related]
6. Adult-Onset Still's Disease in Pregnancy: Lessons Learned and an Approach to Subsequent Pregnancies.
Martinez-King C; Chung SH; McCartney SA
Reprod Sci; 2023 Dec; 30(12):3515-3519. PubMed ID: 37464203
[TBL] [Abstract][Full Text] [Related]
7. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.
Kedor C; Listing J; Zernicke J; Weiß A; Behrens F; Blank N; Henes JC; Kekow J; Rubbert-Roth A; Schulze-Koops H; Seipelt E; Specker C; Feist E
Ann Rheum Dis; 2020 Aug; 79(8):1090-1097. PubMed ID: 32404342
[TBL] [Abstract][Full Text] [Related]
8. Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission.
Giacomelli R; Caporali R; Ciccia F; Colafrancesco S; Dagna L; Govoni M; Iannone F; Leccese P; Montecucco C; Pappagallo G; Pistone G; Priori R; Ruscitti P; Sfriso P; Cantarini L;
Autoimmun Rev; 2023 Dec; 22(12):103400. PubMed ID: 37482365
[TBL] [Abstract][Full Text] [Related]
9. Case report: Methotrexate's role as a potential inducer of macrophage activation syndrome in Still's disease.
Aldrea F; Klib M; Jalal S; Najak A; Aji W
Int J Rheum Dis; 2024 May; 27(5):e15183. PubMed ID: 38733089
[No Abstract] [Full Text] [Related]
10. Optimal time of starting tocilizumab in acute phase of adult-onset Still's disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature.
Suzuki S; Kataoka Y; Otani T; Taniguchi Y; Ikeda K; Tamura N; Morimoto S
Clin Rheumatol; 2024 Mar; 43(3):1245-1251. PubMed ID: 38342797
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Metaanalysis of Pharmacological Interventions in Adult-Onset Still Disease and the Role of Biologic Disease-Modifying Antirheumatic Drugs.
Ruscitti P; McGonagle D; Garcia VC; Rabijns H; Toennessen K; Chappell M; Edwards M; Miller P; Hansell N; Moss J; Graziadio S; Feist E
J Rheumatol; 2024 May; 51(5):442-451. PubMed ID: 38302170
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review.
Wang MY; Jia JC; Yang CD; Hu QY
Chin Med J (Engl); 2019 Dec; 132(23):2856-2864. PubMed ID: 31856058
[TBL] [Abstract][Full Text] [Related]
13. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.
Saper VE; Ombrello MJ; Tremoulet AH; Montero-Martin G; Prahalad S; Canna S; Shimizu C; Deutsch G; Tan SY; Remmers EF; Monos D; Hahn T; Phadke OK; Cassidy E; Ferguson I; Mallajosyula V; Xu J; Rosa Duque JS; Chua GT; Ghosh D; Szymanski AM; Rubin D; Burns JC; Tian L; Fernandez-Vina MA; Mellins ED; Hollenbach JA; ;
Ann Rheum Dis; 2022 Mar; 81(3):406-415. PubMed ID: 34789453
[TBL] [Abstract][Full Text] [Related]
14. Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.
Hoffmann MC; Cavalli G; Fadle N; Cantoni E; Regitz E; Fleser O; Klemm P; Zaks M; Stöger E; Campochiaro C; Tomelleri A; Baldissera E; Bittenbring JT; Zimmer V; Pfeifer J; Fischer Y; Preuss KD; Bewarder M; Thurner B; Fuehner S; Foell D; Dagna L; Kessel C; Thurner L
J Clin Immunol; 2024 Jan; 44(2):45. PubMed ID: 38231276
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary alveolar proteinosis in an adult patient affected by Still's disease and recurrent episodes of macrophage activation syndrome.
Bindoli S; Lococo S; Calabrese F; Sfriso P
Joint Bone Spine; 2024 Jan; 91(1):105654. PubMed ID: 37858901
[No Abstract] [Full Text] [Related]
16. The latest advances in the use of biological DMARDs to treat Still's disease.
Di Cola I; Ruscitti P
Expert Opin Biol Ther; 2024; 24(1-2):63-75. PubMed ID: 38284774
[TBL] [Abstract][Full Text] [Related]
17. Pyroptosis: the potential eye of the storm in adult-onset Still's disease.
He X; You R; Shi Y; Zeng Z; Tang B; Yu J; Xiao Y; Xiao R
Inflammopharmacology; 2023 Oct; 31(5):2269-2282. PubMed ID: 37429997
[TBL] [Abstract][Full Text] [Related]
18. Adult-onset Still's disease after environmental exposure while working in Africa.
Gilbert EL; Wang B
BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34711620
[TBL] [Abstract][Full Text] [Related]
19. Still's disease continuum from childhood to elderly: data from the international AIDA Network Still's disease registry.
Vitale A; Caggiano V; Lopalco G; Mayrink Giardini HA; Ciccia F; Almaghlouth IA; Ruscitti P; Sfikakis PP; Tufan A; Dagna L; Giacomelli R; Hinojosa-Azaola A; Ragab G; Direskeneli H; Fotis L; Sota J; Iannone F; Morrone M; de Brito Antonelli IP; Dagostin MA; Iacono D; Patrone M; Asfina K; Alanazi F; Di Cola I; Gaggiano C; Tektonidou MG; Kardas RC; Kucuk H; Campochiaro C; Tomelleri A; Navarini L; Berardicurti O; Martín-Nares E; Torres-Ruiz J; Mahmoud AAA; Alibaz-Oner F; Kourtesi K; Tarsia M; Sfriso P; Makowska J; Govoni M; La Torre F; Maggio MC; Monti S; Del Giudice E; Emmi G; Bartoloni E; Hernández-Rodríguez J; Gómez-Caverzaschi V; Maier A; Simonini G; Iagnocco A; Conti G; Olivieri AN; De Paulis A; Lo Gullo A; Viapiana O; Wiesik-Szewczyk E; Erten S; Ogunjimi B; Carubbi F; Tharwat S; Laskari K; Costi S; Triggianese P; Karamanakos A; Conforti A; Frassi M; Sebastiani GD; Gidaro A; Mauro A; Balistreri A; Fabiani C; Frediani B; Cantarini L
RMD Open; 2023 Dec; 9(4):. PubMed ID: 38053457
[TBL] [Abstract][Full Text] [Related]
20. The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still's disease.
Nigrovic PA; de Benedetti F; Kimura Y; Lovell DJ; Vastert SJ
Pediatr Rheumatol Online J; 2024 Jan; 21(Suppl 1):114. PubMed ID: 38183114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
